BIOLQ (Biolase) ROE % Adjusted to Book Value: 0.00% (As of Sep. 2024)


BIOLQ Biolase Inc BIOLQ
16 GF Score
Price $0.00
View Full Analysis

What is Biolase ROE % Adjusted to Book Value?

Biolase BIOLQ -99.00% 16 ROE % Adjusted to Book Value is 0.00% as of Sep. 2024. GuruFocus rates BIOLQ with a GF Score™ of 16/100.

Biolase's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Biolase's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Biolase's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Biolase ROE % Adjusted to Book Value Related Terms

Biolase ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Biolase's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolase ROE % Adjusted to Book Value Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.54 -78.90 -38.86 -186.55 0.00

Biolase Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.74 0.00 0.00 0.00 0.00

BIOLQ vs OPGN, AFIB, ABT: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, Biolase's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolase ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biolase's ROE % Adjusted to Book Value falls into.


BIOLQ
16GF Score
Biolase Inc BIOLQ
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biolase ROE % Adjusted to Book Value Calculation

Biolase's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-888.93% / N/A
=N/A

Biolase's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Biolase (BIOLQ) has a ROE % Adjusted to Book Value of 0.00% as of Sep. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biolase and its competitors.
Is Biolase's ROE % Adjusted to Book Value too high?
Biolase's current ROE % Adjusted to Book Value is 0.00%. Overall, Biolase has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biolase's ROE % Adjusted to Book Value compare to OPGN and AFIB?
Biolase's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Biolase and its competitors. Biolase's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biolase stock overvalued right now?
Biolase (BIOLQ) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Biolase's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Biolase (BIOLQ), the current ROE % Adjusted to Book Value is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biolase Business Description

Address 27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
16GF Score

Get the complete analysis for BIOLQ

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price